Research programme: Protein degrader therapies - Blueprint Medicines/Proteovant Therapeutics
Latest Information Update: 25 Aug 2023
At a glance
- Originator Blueprint Medicines; Proteovant Therapeutics
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Haematological disorders